BOSTON & SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals (“Overland”) and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed in China with ZYNLONTA® in combination with rituximab compared to standard immunochemotherapy in the LOTIS-5 confirmatory Phase 3 global clinical trial in second-line or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL).
Overland Pharmaceuticals, a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, has announced the appointment of Dr. Xun Liu, as Chief Technology Officer (CTO). In this new role, Dr. Liu will be responsible for overseeing the company’s global technical operations including chemistry, manufacturing, and controls (CMC) of product development and commercialization.
CHARLOTTESVILLE, Va., Dec. 7, 2021/PRNewswire/ -- A large-scale systematic investigation to replicate nhigh-impact, preclinical cancer biology experiments identified barriers to conducting replications and observed weaker evidence for the findings compared with the original experiments. Unnecessary friction in the nresearch process may be slowing the advancement of knowledge, solutions, and treatments.
BOSTON, SHANGHAI, and LAUSANNE, Switzerland - ( BUSINESS WIRE ) - Overland ADCT BioPharma, a joint venture formed by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced that China's first patient ZYNLONTA® was given in a pivotal Phase II clinical trial in patients with relapsed or refractory large B-cell lymphoma (DLBCL). In April 2021, ZYNLONTA was approved as monotherapy by the US Food and Drug Administration (FDA) as the first and only CD19-targeting antibody-drug conjugate (AWK) for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy accelerated approval procedures granted. This local pivotal trial reflects the ongoing global Phase II pivotal clinical trial of ADC Therapeutics' ZYNLONTA. The results of this study support the potential registration of ZYNLONTA in China.
Overland Pharmaceuticals (“Overland”), a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, today announced the appointment of Roger Luo, Ph.D. as Chief Development Officer, Head of Clinical and Preclinical Development. Dr. Luo brings to Overland over 20 years of industry experience in translational research and clinical development for innovative oncology, immunology and hematology therapeutics. In this newly created position, Dr. Luo will be responsible for managing the company’s overarching development function including clinical science, biometrics, clinical operations, pharmacovigilance and clinical pharmacology, in addition to overseeing the buildout of Overland’s preclinical development organization.